Literature DB >> 10705937

Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease.

Y Hasegawa1, T Inagaki, M Sawada, A Suzumura.   

Abstract

OBJECTIVE: Although the pathogenesis of Parkinson's disease (PD) is still unknown, several reports suggest the presence of immunological abnormalities in the patients with PD such as impaired T cell responses or cytokine production by the peripheral immune system. MATERIAL AND
METHOD: In this study, we examined cytokine production by peripheral blood mononuclear cells (PBMC) and monocyte/macrophages (PBM) in the patients with idiopathic PD, using age-related healthy donors as a normal control and cerebrovascular diseases (CVD) as a disease control.
RESULTS: Production of TNF-alpha, IL-1alpha, IL-1beta and IL-6 by PBMC and TNF-alpha by PBM were significantly lower in the patients with PD as compared to the control groups. IFN-gamma production by LPS-stimulated PBMC in the patients with PD was also significantly lower than that in control groups. Cytokine production by PBMC from the patients with CVD who had a similar disability as the patient group was not significantly different from those in normal controls. Thus, impaired production of inflammatory cytokines may not be due to the mental and physical stress caused by their disability.
CONCLUSION: In the patients with PD, a significant negative correlation was noted in 1alpha-1beta, IL-1beta and IL-6 levels produced by LPS-stimulated PBMC and Hoehn Yahr disability score of the patients, suggesting that the impaired cytokine production may progress with disease progression. These abnormalities in cytokine production may not be primary but may affect the prognosis of PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705937     DOI: 10.1034/j.1600-0404.2000.101003159.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  22 in total

Review 1.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 3.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 4.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 5.  Macrophage polarization in response to epigenetic modifiers during infection and inflammation.

Authors:  Urmi Patel; Sheeja Rajasingh; Saheli Samanta; Thuy Cao; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Drug Discov Today       Date:  2016-08-21       Impact factor: 7.851

6.  Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.

Authors:  Natalia Pessoa Rocha; Frankcinéia Assis; Paula Luciana Scalzo; Érica Leandro Marciano Vieira; Izabela Guimarães Barbosa; Mariana Soares de Souza; Paulo Pereira Christo; Helton José Reis; Antonio Lucio Teixeira
Journal:  Mol Neurobiol       Date:  2017-02-07       Impact factor: 5.590

7.  Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease.

Authors:  Yun Su; Changhe Shi; Tai Wang; Chen Liu; Jing Yang; Shuyu Zhang; Liyuan Fan; Huimin Zheng; Xinwei Li; Haiyang Luo; Shuo Zhang; Zhengwei Hu; Yu Fan; Xiaoyan Hao; Chenglin Zhang; Bo Song; Chengyuan Mao; Yuming Xu
Journal:  J Neurol       Date:  2022-07-27       Impact factor: 6.682

Review 8.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.

Authors:  M Reale; N H Greig; M A Kamal
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

9.  Parkinson's disease and systemic inflammation.

Authors:  Carina C Ferrari; Rodolfo Tarelli
Journal:  Parkinsons Dis       Date:  2011-02-22

10.  Niacin Enhancement for Parkinson's Disease: An Effectiveness Trial.

Authors:  Raymond Chong; Chandramohan Wakade; Marissa Seamon; Banabihari Giri; John Morgan; Sharad Purohit
Journal:  Front Aging Neurosci       Date:  2021-06-17       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.